Coupled cross-sectional and longitudinal non-negative matrix factorization reveals dominant brain aging trajectories in 48,949 individuals.
Abstract
Machine learning can unravel heterogeneous patterns of brain aging and neurodegeneration, but existing methods offer limited insights into disease progression due to reliance on cross-sectional data. We introduce Coupled Cross-sectional and Longitudinal Non-negative Matrix Factorization (CCL-NMF) to capture dominant brain aging patterns by simultaneously leveraging cross-sectional and longitudinal neuroimaging data. CCL-NMF allows individuals to co-express multiple patterns, capturing mixed neuropathologic processes. Applied to neuroimaging data from 48,949 individuals from the harmonized iSTAGING study, CCL-NMF identifies seven distinct, reproducible, and biologically relevant neuroanatomical patterns. Subject-specific loading coefficients quantifying the individual expression of these patterns show distinct associations with cognition, genetic, and lifestyle factors. To support broader application, a regression-based tool was developed to estimate loadings in external cohorts without rerunning the full framework. By enabling individualized estimation of distinct brain aging patterns, these findings may improve risk assessment and therapeutic evaluation in neurodegenerative diseases. Although demonstrated using structural MRI, this framework is generalizable to other imaging modalities and biomarker types.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper claims that the Coupled Cross-sectional and Longitudinal Non-negative Matrix Factorization (CCL-NMF) method can identify distinct brain aging patterns that are associated with cognition, genetics, and lifestyle factors. This research is relevant as it seeks to understand and quantify brain aging processes, which are fundamental to addressing age-related diseases and potentially improving longevity through better risk assessment and therapeutic evaluation.
Author of this paper? Send a correction.